AVEO Oncology and HiberCell Sign Agreement for Innovative Cancer Treatment Development AVEO Oncology and HiberCell have partnered to develop a groundbreaking first-in-human PERK inhibitor, HC-5404, to enhance renal cell carcinoma treatments together with FOTIVDA.

AVEO Oncology and HiberCell Sign Agreement for Innovative Cancer Treatment Development #United_States #Boston #AVEO_Oncology #HiberCell #HC-5404